Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127896831 | 12789683 | 1 | I | 2014 | 20160916 | 20160928 | 20160928 | EXP | RU-SA-2016SA174765 | AVENTIS | OVSYANNIKOVA AK, RYMAR OD, SHAKHTSHNEIDER EV, KLIMONTOV VV, KOROLEVA EA, MYAKINA NE, ET AL. ABCC8-RELATED MATURITY-ONSET DIABETES OF THE YOUNG (MODY12): CLINICAL FEATURES AND TREATMENT PERSPECTIVE. DIABETES THER. 2016;7:591-600. DOI: 10.1007/S13300-016-0192-9. ACCESSED: 2016 AUG 18. | 27.00 | YR | A | M | Y | 0.00000 | 20160928 | OT | RU | RU |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127896831 | 12789683 | 1 | PS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Unknown | DOSE:16 UNIT(S) | Y | UNKNOWN | 21081 | INJECTION | QD | ||||||
| 127896831 | 12789683 | 2 | SS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Unknown | DOSE:13 UNIT(S) | Y | UNKNOWN | 21081 | INJECTION | QD | ||||||
| 127896831 | 12789683 | 3 | SS | INSULIN GLARGINE | INSULIN GLARGINE | 1 | Unknown | Y | UNKNOWN | 21081 | INJECTION | ||||||||
| 127896831 | 12789683 | 4 | SS | INSULIN LISPRO | INSULIN LISPRO | 1 | Unknown | 4-6 U | Y | UNKNOWN | 0 | INJECTION | TID | ||||||
| 127896831 | 12789683 | 5 | SS | INSULIN LISPRO | INSULIN LISPRO | 1 | Unknown | BEFORE LUNCH AND DINNER DOSE:4 UNIT(S) | Y | UNKNOWN | 0 | INJECTION | BID | ||||||
| 127896831 | 12789683 | 6 | SS | INSULIN LISPRO | INSULIN LISPRO | 1 | Unknown | 4-6 U | Y | UNKNOWN | 0 | INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127896831 | 12789683 | 1 | Type 1 diabetes mellitus |
| 127896831 | 12789683 | 2 | Type 1 diabetes mellitus |
| 127896831 | 12789683 | 3 | Type 1 diabetes mellitus |
| 127896831 | 12789683 | 4 | Type 1 diabetes mellitus |
| 127896831 | 12789683 | 5 | Type 1 diabetes mellitus |
| 127896831 | 12789683 | 6 | Type 1 diabetes mellitus |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127896831 | 12789683 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127896831 | 12789683 | Diabetic retinal oedema | |
| 127896831 | 12789683 | Diabetic retinopathy | |
| 127896831 | 12789683 | Hypoglycaemia | |
| 127896831 | 12789683 | Visual acuity reduced | |
| 127896831 | 12789683 | Weight increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127896831 | 12789683 | 1 | 2014 | 2015 | 0 | |
| 127896831 | 12789683 | 2 | 2015 | 2015 | 0 | |
| 127896831 | 12789683 | 3 | 2015 | 2015 | 0 | |
| 127896831 | 12789683 | 4 | 2014 | 2015 | 0 | |
| 127896831 | 12789683 | 5 | 2015 | 2015 | 0 | |
| 127896831 | 12789683 | 6 | 2015 | 2015 | 0 |